Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real‐world data from a large multi‐national UCARE study
Allergy2024Vol. 80(2), pp. 489–499
Citations Over TimeTop 10% of 2024 papers
Reineke Soegiharto, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, Esmee van Lindonk, Fatih Demir, Nasser Mohammad Porras, Yoshimi Matsuo, Lea Kiefer, André C. Knulst, Marcus Maurer, Karen Ritchie, Michael Rudenko, Emek Kocatürk, Roberta Fachini Jardim Criado, Stamatios Gregoriou, Tatjana Bobylev, Andreas Kleinheinz, Shunsuke Takahagi, Michihiro Hide, Ana M. Giménez‐Arnau, Andaç Salman, Rabia Öztaş Kara, Bahar Sevimli Dikicier, Martijn B. A. van Doorn, Simon Francis Thomsen, J. M. P. A. van den Reek, Heike Röckmann
Abstract
Omalizumab is highly effective and safe in CIndU patients, with long estimated treatment duration mainly reflecting long disease duration. Our data show omalizumab's high potential as treatment in any subtype of CIndU and support its clinical use for these patients.
Related Papers
- → EFFECT OF OMALIZUMAB ON PATIENTS WITH CHRONIC URTICARIA: ISSUES WITH THE DETERMINATION OF AUTOIMMUNE URTICARIA(2008)12 cited
- → OMALIZUMAB AS A THERAPEUTIC ALTERNATIVE FOR CHRONIC URTICARIA(2008)9 cited
- → The Potential Role of Omalizumab in the Treatment of Chronic Urticaria(2014)3 cited
- → Effects of omalizumab on chronic urticaria not responding to recommended therapy(2012)
- → Follow-up of asthma control and quality of life after discontinuation of omalizumab in severe asthmatic patients(2015)